Advertisement

Topics

Clinical Trials About "Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis" - Page: 5 RSS

19:29 EST 16th December 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis" on BioPortfolio

We have published hundreds of Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis news stories on BioPortfolio along with dozens of Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis Clinical Trials and PubMed Articles about Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis Companies in our database. You can also find out about relevant Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis Drugs and Medications on this site too.

Showing "Thermography Assessing Treatment Response Golimumab Psoriatic Arthritis" Clinical Trials 101–125 of 28,000+

Relevant

Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions

A total of approximately 500 patients with active psoriatic arthritis in an estimated 80 to 100 trial centers are to be enrolled. Selection of centers will be made by the sponsor's medical section. To increase the quality of the data and to reduce distribution of the data collected, centers to be included will be those which can enroll at least 5 patients. Care will be taken to ensure a balanced regional distribution. The proposed observation period for the trial is approx. 52 ...


Disparity Between Ultrasound- and Clinical Findings in Psoriatic Arthritis in Remission

Comparison of the proportion of Psoriatic arthritis patients in ultrasound remission (i.e. no power Doppler synovitis, tenosynovitis, dactylitis, enthesitis, PD=0) depending on whether patient and physician's global assessment of disease activity are in agreement or in disagreement.

BI655066 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

This is a confirmatory, multicentre, randomized, double-blind, placebo controlled, 104 week study with a 88 week treatment period and a 16 week follow-up period evaluating the efficacy and safety of BI 655066 to support Registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients. This study will also look at the maintenance of response following randomly withdrawing treatment from those patients responding to treatment at week 28, as well as ...


Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists

The purpose of this study is to evaluate the safety profile and the effectiveness of Etanercept under usual care settings in patients with PsA treated by dermatologists.

Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists

The purpose of this study is to evaluate the safety and effectiveness of Etanercept under usual care settings in patients with PsA treated by rheumatologists.

The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory condition causing continuous mucosal inflammation of the colon, which is accompanied by episodes of bloody diarrhoea and abdominal pain. Both infliximab and adalimumab have been used with success for moderate-to-severe UC refractory to conventional therapy. More recently, golimumab, another anti-TNF antibody, has been added to the treatment armamentarium. In the multi-centre, double-blind, placebo-controlled PURSUIT trial, pati...

Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls

In this trial different parts of the pain signalling system involved in two rheumatic diseases - painful hand osteoarthritis and psoriatic arthritis, is examined. These measurements will be compared to those of healthy volunteers The hypothesis is that patients with hand osteoarthritis and psoriatic arthritis react differently to painful and non-painful stimuli compared with the healthy volunteers. The aim is to recruit 66 patients with painful hand-osteoarthritis, 66 patient...

Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA

Methotrexate (MTX) co-medication can improve the therapeutic effect of biological therapies (e.g. Tumor necrosis factor (TNF) -inhibitors) in rheumatoid arthritis (RA), but its role in Psoriatic Arthritis (PsA) remains unclear. No data from Randomized Clinical Trials (RCTs) are available to address the questions whether add-on of MTX to UST monotherapy, or a withdrawal of continuous MTX therapy in patients with newly initiated Ustekinumab (UST) treatment or simultaneously indu...

A Study of the Safety and Efficacy of CNTO 1275 in Patients With Active Psoriatic Arthritis

The purpose of this study is to evaluate the effiacy (improvement of signs and symptoms) and safety of an antibody to IL-12 (interleukin: protein used to stimulate immune systems) and IL-23 [CNTO 1275] in psoriatic arthritis.

Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis

This study aims to characterize the changes on intestinal microbiota pattern associated with the use of golimumab in order to determine if intestinal microbiota markers may correlate with golimumab therapeutic effect in patients naïve & non-naïve to anti-TNF treatment

A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014179)

The purpose of this study is to assess the effects (good and bad) of CNTO 148 (golimumab) therapy in patients with ulcerative colitis

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

The purpose of this study is to determine whether DC-STAMP, a protein on the surface of osteoclast precursors (OCPs), can be used as a biologic marker in Psoriatic Arthritis (PsA). With this marker the investigators hope to learn more about how OCPs develop as well as find out if DC-STAMP predicts PsA severity and how well treatment works in PsA.

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in subjects with psoriatic arthritis. To do this, etanercept alone will be compared to methotrexate alone or to combination etanercept and methotrexate.This study will last approximately 1 year (52 weeks) for an individual subject. Subjects will be randomized into 1 of 3 groups. Subjects will have a 1 in 3 chance of receiving etanercept p...

Comparation of Ultrasonic Imaging of Enthesopathy in Patients With Psoriatic Arthritis and Psoriasis

Psoriatic arthritis(PsA) and psoriasis(Ps) are two systemic inflammatory diseases linked with rash of psoriasis, but there's still great controversy regarding the exact relationship between them. Our study is to investigate the characteristics and differences of the ultrasonic imaging of enthesopathy in the lower extremity in patients with PsA and Ps, to explore the risk factors of Ps developing into PsA in the long term course.

Correlation of Soluble ST2 With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).

The purpose of this study is to evaluate serum soluble human Suppression of Tumorigenicity 2 (ST2) protein, the receptor for IL-33 and a member of the proinflammatory IL-1 receptor superfamily, as a surrogate biological marker predictive of disease outcome and therapeutic response to golimumab treatment in subjects with moderate to severe UC who have failed on prior conventional therapies. The primary endpoints of this study are to correlate serum soluble ST2 levels with endosc...

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

The purpose of this study is to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 24, to support the use of secukinumab pre-filled syringe (PFS) by subcutaneous (s.c.) self-administration with or without loading regimen in subjects with active Psoriatic Arthritis (PsA) despite current or previous NSAID, DMARD therapy and/or previous anti-TNFα therapy. Long term efficacy up t...

Distal Erosions and Nail Psoriasis

Nearly 30% of patients with cutaneous psoriasis (PsO) developed psoriatic arthritis (PsA). Among these patients 20 % will have severe destructive arthritis. The risk of developing PsA is significantly higher in patients with nail involvement (OR = 2.24; 95% CI [1.26-3.98]). The risk is particularly high for the peripheral form of PsA and onycholysis (OR=2.80; 95% CI [1.34-5.85]). Thus we wanted to test the hypothesis that onycholysis, in patients without PsA, is a potent...

Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by inflammatory arthritis and enthesitis involving the spine. AxSpA prevalence is around 0.17% of the French population. Tumor necrosis factor (TNF) was the first target defined in axSpA. Since one third of axSpA patients failed to the first TNF blocker, many axSpA patients received a second biological Disease-Modifying AntiRheumatic Drugs (bDMARDs). Until few months, the only choice was to use a se...

Safety and Efficacy of Secukinumab in Mild Psoriasis

Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mild psoriasis with a short-term anti- interleukin (IL)-17A treatment, investigators may reduce the costs of treating psoriasis and associated medical conditions, including psoriatic arthritis, cardiovascular disease, and diabetes.

Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic arthritis (PsA)] who have completed approximately 96 weeks of participation in study 0881A1-3338 (B1801014). The study contains an active treatment period, withdrawal/re-treatment period and a observational period (non-treatment).

Evaluation of Peripheral Microcirculation Hemodynamics Following Various Changes Based on Noninvasive Thermography

The objective of the current study is to investigate the hemodynamic changes in the peripheral microcirculation system as a response to various changes, using noninvasive thermography and laser doppler

PsA Secukinumab XCT Structural Progression Study

Psoriatic arthritis is related with chronic inflammation and progressive radiographic damages, and it in turn lead to disability and loss in function-ability. Recent advance in treatment pathway through anti IL-17 gives promising clinical improvement. Yet, its effect on radiographic progression remains uncertain. This study aimed to ascertain the effect of secukinumab on structural progression in PsA by evaluation through high resolution peripheral quantative computed tomograph...

A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.

A long term study to demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.

Golimumab Trough Levels in Patients With Ulcerative Colitis

Proactive therapeutic drug monitoring of Anti-TNFs with drug titration to a therapeutic window is associated with favorable long-term therapeutic outcomes in IBD and may be superior to reactive therapeutic drug monitoring. Moreover, many exposure-response relationship studies have shown that higher serum anti-TNF drug concentrations are associated with better clinical outcomes in IBD, suggesting that it is maybe time to go from a 'treat-to-target' to a 'treat-to trough' therape...

REMission INDuction in Very Early Rheumatoid Arthritis

Rheumatoid arthritis (RA) patients in remission with a combination of TNFinhibitors (TNFi) and methotrexate (MTX) often express their wish to stop MTX treatment because of side effects. Given the efficacy of TNFi it is conceivable that in early RA patients in remission with methotrexate (MTX)/TNFi stepwise discontinuation of MTX prior to TNFi is superior in maintaining sustained remission and reaching drug free remission as compared to discontinuation of TNFi prior to MTX. ...


More From BioPortfolio on "Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis"

Advertisement
Quick Search
Advertisement
Advertisement